Abstract
Background We report on a patient with rheumatoid arthritis (RA) who was treated with adalimumab and retrospectively diagnosed as having a multiple myeloma.
Investigations In addition to the determination of clinical symptoms, investigations included radiography of the thorax, spine, hands and feet, arthrosonography, determination of laboratory parameters (including C-reactive protein levels and presence of antibodies against cyclic citrullinated peptide), cytogenetics and electrocardiography.
Diagnosis RA was initially diagnosed in 1988. Stage II and stage III RA were diagnosed for the left and right foot, respectively, in 1996. Joints of both hands were diagnosed with stage I RA; both wrists and some finger joints showed signs of synovitis. Plasmocytoma was diagnosed in 2004; however, investigation of medical records revealed evidence of multiple myeloma 8 years earlier, in 1996.
Management RA was originally treated with gold, sulfasalazine, azathioprin and glucocorticoid. Methotrexate was later used in addition to cortisone and then in combination with a selective cyclo-oxygenase-2 inhibitor. A combination therapy consisting of adalimumab (40 mg every 2 weeks), methotrexate (15 mg weekly) and a cyclo-oxygenase-2 inhibitor (rofecoxib 25 mg daily until July 2004, etoricoxib 90 mg daily from October 2004) was started in November 2003. Adalimumab therapy was interrupted for 6 months owing to safety concerns, but was resumed after a careful risk–benefit assessment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Steinbrocker O et al. (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140: 659–662
Durie BG and Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842–854
Usnarska-Zubkiewicz L et al. (1997) Rheumatoid arthritis as a risk factor for development of multiple myeloma [Polish]. Pol Arch Med Wewn 97: 253–259
Voulgari PV and Drosos AA (2006) Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 6: 1349–1360
Furst DE et al. (2006) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 65: iii2–iii15
Mellemkjaer L et al. (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A: 1753–1757
Baecklund E et al. (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case–control study. BMJ 317: 180–181
Schiff M et al. (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889–894
HUMIRA Summary of Product Characteristics (Fachinformation), Nov 2006 [http://www.fachinfo.de or http://www.emea.europa.eu/] (accessed 18 January 2008)
Watson KD et al. (2006) Influence on the anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA); results from the BSR biologics register [abstract]. Ann Rheum Dis 65: S512
Wolfe F and Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 56: 2886–2895
Askling J et al. (2005) Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics following TNF-antagonists. Ann Rheum Dis 64: 1414–1420
Setoguchi S et al. (2006) Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54: 2757–2764
Baecklund E et al. (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: 692–701
Jourdan M et al. (1999) Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 10: 65–70
Brar A et al. (2007) Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy? Nat Clin Pract Rheumatol 3: 120–121
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mielke, F., Schweigert, M. Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. Nat Rev Rheumatol 4, 218–221 (2008). https://doi.org/10.1038/ncprheum0761
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0761
This article is cited by
-
Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing
Dermatology and Therapy (2020)